Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Imbruvica plus Rituxan delayed disease progression when compared with a triple chemotherapy regimen.
Customized treatments demonstrate good response rates for mantle cell lymphoma and chronic lymphocytic leukemia.
In my post-diagnosis, post-chemo world, irrational anxiety has become my near-constant companion.
I was recently reminded — repeatedly — by my 10-year-old son of how much my cognitive ability has been impacted by cancer and chemo.
Perhaps more fundamentally, being otherwise occupied has distracted me to a degree from the omnipresence of cancer.
There is something so profoundly altering about being diagnosed with cancer that it results in a new understanding of what is important.
I can’t think of a single positive reason one would ever go to an oncologist.
I have a steadfast belief that the last place one wants to be when ill is at the hospital—After all, there are sick people there.
Imbruvica, Calquence and Venclexta demonstrate good results in combination regimens.
Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
Just because I look quite healthy does not mean that I am. To quote my oncologist prior to chemo, “You had no idea how sick you were.”
There are only so many incurable, life-altering diseases that one is really game for. And I think I have already reached my quota.
To hopefully put some context to all of this cancer talk, it is probably a useful exercise for me to share a bit about who I am.
Sometimes conflict is unavoidable and the past few days conspired to put such discord in my path.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.